Status:
COMPLETED
Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Controlled Ovarian Stimulation
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to monitor the use in routine clinical practice of REKOVELLE®. This study will collect information from patients who never underwent previous in vitro fertilisation (IVF) ...
Eligibility Criteria
Inclusion
- Patients who meet all of the following criteria are eligible for participation:
- Females are prescribed REKOVELLE® for their first in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor
- Willing and able to provide written informed consent
Exclusion
- Patients who meet any of the following criteria are not eligible for participation:
- Participating in an interventional clinical trial in which any treatment or follow-up is mandated
- Women with a contraindication for prescription of REKOVELLE® treatment
- Oocyte donors
- Women undergoing ovarian stimulation for fertility preservation
Key Trial Info
Start Date :
March 16 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 17 2020
Estimated Enrollment :
1018 Patients enrolled
Trial Details
Trial ID
NCT03393780
Start Date
March 16 2018
End Date
July 17 2020
Last Update
February 9 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Melbourne - IVF (there may be other sites in this country)
East Melbourne, Australia
2
Landeskrankenhaus Feldkirch Kinderwunschzentrum (there may be other sites in this country)
Feldkirch, Austria
3
UZ Brussel (there may be other sites in this country)
Brussels, Belgium
4
Clinique - OVO (there may be other sites in this country)
Montreal, Canada